Register for our Binding Site Central & Eastern European webinar series

We are pleased to announce the launch of our educational webinar series focussing on the clinical applications of our Freelite assays in different monoclonal gammopathies and neurological disorders, presented by Dr. James Last, Field Medical Science Liaison Lead.

Please join us for this exciting monthly series, as scheduled below.

1. Monday 30^th January 2023 (3pm CEST) - Introduction to Freelite: The technology behind Binding Site assays and its advantages versus Total Light Chains, Monoclonal assay and Urine testing
   
2. Monday 27^th February 2023 (3pm CEST) - Freelite in Multiple Myeloma diagnosis
3. Monday 27^th March 2023 (3pm CEST) - Freelite for primary care physicians - Maybe it's Myeloma?
4. Monday 24^th April 2023 (3pm CEST) - Freelite in Multiple Myeloma monitoring
5. Monday 29^th May 2023 (3pm CEST)  - Freelite in Monoclonal Gammopathies of Undetermined Significance and Smoldering Multiple Myeloma. iStopMM clinical trial update
6. Monday 26^th June 2023 (3pm CEST) - Freelite in nephrology
7. Monday 25^th September 2023 (3pm CEST) - Serum Free Light Chains in Osteoporosis and bone fractures
8. Monday 30^th October 2023 (3pm CET) - Freelite in AL Amyloidosis and cardiac amyloidosis 
9. Monday 27^th November 2023 (3pm CET) - Freelite in CSF - focus on neurological disorders 

If you missed any of our webinars, you watch them here:

Speaker Bio:

Dr. James Last is the Field Medical Science Liaison Lead at The Binding Site, part of Thermo Fisher Scientific. James achieved his undergraduate degree in Molecular Cell Biology at The University of Nottingham, UK before completing his PhD in Cancer Sciences at the University of Birmingham, UK. Following 8 years post-doctoral research, James joined The Binding Site as a Medical Science Liaison in 2013, providing educational seminars on the clinical utility of Binding Site technologies as well as organising national and international trials to evaluate these assays. More recently, James has progressed into his current role managing and coordinating the scientific activities of the International Sales Medical Science Liaison team. In January 2023, Thermo Fisher Scientific purchased The Binding Site and created the Protein Diagnostics unit, as part of the Specialty Diagnostics Group.